Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 126 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma December 11, 2024 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 Load more HOT NEWS Adding More Mushrooms to Your Diet May Decrease Your Risk of... Investigating suspected prostate cancer: improving GP-patient communication FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer
